爱朋医疗(300753) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was ¥92,480,163.03, a decrease of 2.95% compared to the same period last year[4] - Net profit attributable to shareholders was ¥7,894,887.15, an increase of 255.22% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥5,836,908.38, up 217.80% from the previous year[4] - The company's net profit attributable to shareholders decreased to ¥170,355,620.81 from ¥190,032,945.68, a drop of 10.4%[17] - The net profit for the current period is -12,288,412.34, compared to a net profit of 3,871,895.24 in the previous period, indicating a significant decline[19] - Operating profit for the current period is -20,717,716.75, while the previous period reported an operating profit of 12,974,498.00, reflecting a substantial decrease[19] - The total comprehensive income for the current period is -12,288,412.34, compared to 3,871,895.24 in the previous period, showing a significant drop[19] - The basic and diluted earnings per share for the current period are both -0.0911, compared to 0.0302 in the previous period[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥839,641,329.18, a decrease of 2.76% from the end of the previous year[4] - The company's cash and cash equivalents decreased to ¥145,673,239.26 from ¥201,635,257.87, a decline of 27.8%[15] - Total assets decreased to ¥839,641,329.18 from ¥863,485,234.50, a reduction of 2.8%[16] - Total liabilities decreased slightly to ¥153,564,161.15 from ¥155,622,128.21, a decline of 1.3%[16] - Current liabilities totaled ¥127,060,432.65, a slight increase from ¥125,619,973.03, reflecting a growth of 1.1%[16] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥50,180,829.57, a decrease of 50.53% year-on-year[4] - Cash flow from operating activities shows a net outflow of -50,180,829.57, compared to a net outflow of -33,336,214.47 in the previous period, indicating worsening cash flow conditions[20] - Cash flow from investing activities shows a net outflow of -17,903,425.18, compared to -96,933,485.73 in the previous period, indicating improved investment cash flow[21] - Cash flow from financing activities resulted in a net inflow of 12,122,236.14, contrasting with a net outflow of -4,036,038.24 in the previous period, showing a positive shift in financing[21] - The company received 73,700,000.00 in borrowings during the current period, an increase from 48,400,000.00 in the previous period, indicating increased leverage[21] Shareholder Information - The total number of common shareholders at the end of the reporting period is 22,128[10] - Wang Ningyu holds 28.62% of shares, totaling 36,069,811 shares, with 8,600,000 shares pledged[10] - Zhang Zhihui holds 10.46% of shares, totaling 13,179,428 shares[10] - The total number of restricted shares at the end of the period is 38,153,964, with 5,472,212 shares released during the period[12] - The total number of shareholders for preferred shares is not applicable[11] Investments and Acquisitions - The company reported a significant increase in investment income by 339.15% due to higher earnings from joint ventures[8] - The company experienced a 400.35% increase in net cash flow from financing activities, primarily due to new short-term borrowings[8] - The company’s goodwill increased by 44.12% due to the acquisition of a subsidiary[8] - The company reported a significant increase in goodwill to ¥78,842,117.94 from ¥54,705,759.84, an increase of 43.9%[16] - Long-term equity investments increased to ¥58,782,533.88 from ¥52,393,867.86, a growth of 12.5%[15] Research and Development - Research and development expenses rose to ¥28,911,852.32, an increase of 23.4% compared to ¥23,409,768.84 in the previous period[18] - The company’s subsidiary obtained a medical device registration certificate for portable EEG machines, enhancing its product offerings[13] - The company plans to expand its market presence with new medical technology products[13] Management and Governance - The company has completed the election of the board of directors and the appointment of senior management[13] - Senior management member Li Qing reduced his shareholding by 119,174 shares, representing 0.0945% of the total share capital[13] Reporting Period - The company's financial report is prepared as of September 30, 2025[14] - Total operating revenue for the current period was ¥251,646,851.61, a decrease of 8.4% compared to ¥274,753,514.10 in the previous period[18] - Total operating costs increased to ¥281,294,518.85, up 3.4% from ¥271,029,178.03 in the previous period[18]